Furosemide
- Generic Name
- Furosemide
- Brand Names
- Furoscix, Lasix
- Drug Type
- Small Molecule
- Chemical Formula
- C12H11ClN2O5S
- CAS Number
- 54-31-9
- Unique Ingredient Identifier
- 7LXU5N7ZO5
- Background
Furosemide is a potent loop diuretic that acts on the kidneys to ultimately increase water loss from the body. It is an anthranilic acid derivative. Furosemide is used for edema secondary to various clinical conditions, such as congestive heart failure exacerbation, liver failure, renal failure, and high blood pressure. It mainly works by inhibiting electrol...
- Indication
Furosemide is indicated for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome, in adults and pediatric patients.
...
- Associated Conditions
- Acute Pulmonary Edema, Ascites, Body Fluid Retention, Edema, Hypertension, Mild to Moderate Hypertension, Chest congestion
- Associated Therapies
- -
A Study in Healthy Men to Test Whether Zongertinib Influences the Amount of 4 Other Medicines (Dabigatran, Rosuvastatin, Metformin, and Furosemide) in the Blood
- Conditions
- Interventions
- First Posted Date
- 2024-07-17
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 32
- Registration Number
- NCT06504862
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
Diuretics vs. Afterload Reduction for Treatment of HeartLogic Alerts
- Conditions
- Interventions
- First Posted Date
- 2024-01-23
- Last Posted Date
- 2024-01-29
- Lead Sponsor
- Heart Center Research, LLC
- Target Recruit Count
- 80
- Registration Number
- NCT06218199
- Locations
- 🇺🇸
Heart Center Research, LLC, Huntsville, Alabama, United States
A Study of Ultra High Dose Diuretics to Treat Heart Failure
- Conditions
- Interventions
- First Posted Date
- 2023-09-14
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 20
- Registration Number
- NCT06036914
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Diuretic Strategies in Acute Heart Failure Patients at High Risk for Diuretic Resistance
- Conditions
- Interventions
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Stadtspital Zürich
- Target Recruit Count
- 75
- Registration Number
- NCT05986773
- Locations
- 🇨🇭
Stadtspital Zürich, Zürich, Switzerland
Voxelotor CYP and Transporter Cocktail Interaction Study
- First Posted Date
- 2023-08-08
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 44
- Registration Number
- NCT05981365
- Locations
- 🇺🇸
ICON Early Phase Services, LLC, San Antonio, Texas, United States
Diuretic Efficacy of Aminophylline and Furosemide Combination vs Furosemide Alone in Critically Ill Adults
- First Posted Date
- 2023-07-06
- Last Posted Date
- 2023-07-11
- Lead Sponsor
- University of Malaya
- Target Recruit Count
- 132
- Registration Number
- NCT05933642
- Locations
- 🇲🇾
University of Malaya, Kuala Lumpur, Malaysia
Diuretic Use in Hemodialysis Patients With Residual Renal Function
- Conditions
- Interventions
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 34
- Registration Number
- NCT05915286
- Locations
- 🇨🇦
University of Alberta, Edmonton, Alberta, Canada
Combination Diuretic Therapy for Acute Decompensated Heart Failure
- Conditions
- Interventions
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2023-05-03
- Lead Sponsor
- Ochsner Health System
- Registration Number
- NCT05840536
- Locations
- 🇺🇸
Ochsner Heart and Vascular Institute, New Orleans, Louisiana, United States
Comparison of 18F-rhPSMA-7.3 PET/CT With and Without Furosemide in Biochemical Recurrence of Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-03-22
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Emory University
- Target Recruit Count
- 20
- Registration Number
- NCT05779943
- Locations
- 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸Emory Johns Creek Hospital, Johns Creek, Georgia, United States
The Addition of Inhaled Furosemide to Standard Treatment of COPD Exacerbation
- Conditions
- Interventions
- First Posted Date
- 2023-03-15
- Last Posted Date
- 2023-03-15
- Lead Sponsor
- American University of Beirut Medical Center
- Target Recruit Count
- 200
- Registration Number
- NCT05769738
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.